Journal article
Phase I trial and pharmacokinetics of a daily x 5 schedule of 3-deazauridine
Cancer treatment reports, Vol.66(1), pp.81-84
01/01/1982
PMID: 7053271
Abstract
The uridine analog 3-deazauridine has been given to 19 patients in a phase I and pharmacokinetic study. Only mild toxicity was seen at doses less than 1200 mg/m2/day for 5 days. At a dose of 1200 mg/m2/day x 5, leukopenia (mean wbc count nadir of 2650/mm3) was seen in nine of 12 patients and thrombocytopenia (mean platelet count nadir of 47,000/mm3) in five of 12 patients. Nausea and vomiting and oral toxicity were each seen in two patients, and diarrhea and skin toxicity occurred in one patient each. Pharmacokinetic studies indicate a biphasic plasma decay with a beta-half-life of 6.9 hours and urinary excretion, mostly of unchanged drug, as the most important route for drug elimination. A dose of 1200 mg/m2/day x 5 is recommended for phase II studies and great caution is advised in administering the drug in the presence of renal impairment.
Details
- Title: Subtitle
- Phase I trial and pharmacokinetics of a daily x 5 schedule of 3-deazauridine
- Creators
- P J CreavenR L PrioreA MittelmanS BrunoE S HendersonY M RustumJ K Solomon
- Resource Type
- Journal article
- Publication Details
- Cancer treatment reports, Vol.66(1), pp.81-84
- PMID
- 7053271
- ISSN
- 0361-5960
- Language
- English
- Date published
- 01/01/1982
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359761302771
Metrics
13 Record Views